Dateline City:
KENILWORTH, N.J.
Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new and updated findings investigating the use of
KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy,
in multiple gastrointestinal cancers will be presented at this years
Gastrointestinal (GI) Cancers Symposium in San Francisco, Jan. 21 23.
Updates on pembrolizumab include data on advanced esophageal carcinoma
and new preliminary Phase 2 safety data in gastric cancer.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more